Studies
Study summaries, guides, and site news. For discussion and lab results, head to the forum.
- The FDA’s 2026 peptide compounding changes, explained BPC-157, TB-500, and ten other peptides came off the FDA’s restricted list, and an advisory panel backed six for compounding. Here is what actually changed and what hasn’t.
- Retatrutide’s Phase 3 results: what four trials showed Lilly’s triple-agonist produced average weight loss approaching 30% in its pivotal trials. A look at the numbers, the side effects, and the timeline to approval.
- GHK-Cu: what 50 years of copper peptide research supports Strong evidence for skin and wound repair, intriguing gene-expression data, and very little on injection. Where the research on GHK-Cu actually stands.
- Welcome to the new Peptide Source The site has been rebuilt from scratch around what matters most here: the forum, the community’s recommended vendors, and a proper home for articles.
- How semaglutide lowers body weight: inside a 2020 rodent study Weight loss came from eating less, not burning more, and the drug reached appetite centers without crossing the blood-brain barrier.
- Selank and diazepam under chronic stress: a 2017 rat study Combining Selank with diazepam reduced anxiety-like behavior more than diazepam alone in chronically stressed rats. What that suggests, and why it calls for caution.
- Melanotan II and social behavior in a mouse model of autism A week of Melanotan II restored social behavior in a maternal immune activation mouse model. What the study shows, and the caveats that matter.
- BPC 157 and glaucoma: what the rat studies show A 2023 review pulls together BPC 157 research on glaucoma, retinal damage, and corneal injury. Consistent results in rats, with no human eye data yet.
- Thymosin beta-4 and Alzheimer’s: two studies, and what they mean for TB-500 Mouse and human organoid studies both link thymosin beta-4 to less amyloid and healthier neurons. Why that doesn’t yet make TB-500 an Alzheimer’s treatment.